Naobios and Olon France partner to deliver process-specific HCP ELISA for an international academic institute
Two France BioLead members collaborate to provide cutting-edge analytical expertise and ensure reliable supply of process-specific HCP ELISA kits for an international vaccine project.
Nantes & Toulouse, France – October 2, 2025 – Naobios (Clean Biologics Group) and Olon France (part of Olon Group) today announced their collaboration on the development of a process-specific host cell protein (HCP) ELISA kit to support the production of a viral vaccine entering Phase I clinical trials in the second half of 2026.
The partnership was initiated to address a critical analytical need that emerged during the client’s development program. Standard commercial kits are not available for the cell strain used, making a process-specific solution essential to maintain clinical timelines and secure long-term supply.
The project follows a two-step approach designed to align with clinical timelines and project requirements. First, a fast-track HCP ELISA is being developed to enable early detection of HCPs during process development, allowing qualification of the industrial process without delaying the clinical program. This will be followed by a full process-specific ELISA, fine-tuned for GMP release testing of clinical batches. Alongside the analytical work, Olon France and Naobios have worked in close coordination on HCP material production, combining their expertise to achieve robust and reliable results from the outset.
By selecting a process-specific ELISA, the client is assured of long-term availability of kits and reagents, supporting the entire lifecycle of the vaccine program. This reliability is critical to advancing the clinical trials without disruption and highlights the importance of strong analytical strategies in global biopharmaceutical development.
“Olon France is proud to join forces with Naobios to deliver a fully customized HCP ELISA solution, ensuring reliable analytics and supply for our client’s innovative vaccine program. This partnership demonstrates our agility and commitment to advancing complex clinical projects on a global scale” said Jérôme Bedier, CEO of Olon France.
“Partnering with Olon France enables us to strengthen our offering and deliver reliable analytical solutions to our clients. This collaboration exemplifies how French expertise can contribute to international clinical programs,” added Eric Le Forestier, Managing Director of Naobios.
This partnership also underscores the strength of the French biopharmaceutical ecosystem, with two members of France BioLead working side by side as a true ‘lab next door’ to provide dependable analytical support fully integrated into ongoing development programs.
About Naobios (Clean Biologics Group)
Naobios is a Contract Development and Manufacturing Organization (CDMO) providing bioprocess development and offering GMP production of clinical batches of BSL2/BSL3 viral vaccines, oncolytic viruses, challenge agents, viral vectors and exosomes. Naobios joined the Clean Biologics group in 2019.
Having built up 20 years’ experience in bioprocess development, Naobios helps its clients to bring their drug candidates to the clinical stage as quickly as possible – with the highest level of quality – whilst building on its technical know-how in scalable and industrial processes. With its adaptability and range of skills, Naobios can lead a project from the initial stages to completion, with a motivated and dedicated team. Its highly qualified staff has the experience to deal with a wide range of viruses, as well as multiple lines of cell substrate.
Naobios is based near Nantes, in Western France.
About Olon France
Olon France, part of the Olon Group, is a Contract Development and Manufacturing Organization (CDMO) dedicated to supporting biotech and pharmaceutical companies from preclinical development through to commercial supply.
Building on recognized expertise in process development, Olon France provides GMP manufacturing of biologics, bioconjugates such as antibody-drug conjugates (ADCs), and nanoformulated drugs, using both mammalian and microbial systems. With the ability to manage the entire biotherapeutics value chain—from cell line and strain development to aseptic fill-finish—the company offers fully integrated solutions designed to accelerate and secure its clients’ development programs.
